Lutein-zeaxanthin shows continued benefit in AREDS2 supplement for AMD

733426

Sumary of Lutein-zeaxanthin shows continued benefit in AREDS2 supplement for AMD:

  • “It is not recommended for smokers, as beta-carotene increased the risk for lung disease among smokers in two NIH studies.”.
  • The AREDS2 study, conducted between 2006 and 2012, was designed to assess the effects of adding lutein-zeaxanthin and omega-3 fatty acids to the AREDS formulation on AMD outcomes..
  • Results showed a twofold increased risk for lung cancer among randomized patients who received the standard AREDS formulation that contained beta-carotene, whereas those who received AREDS with lutein-zeaxanthin showed incremental benefits in reduced progression to late AMD..
  • “Safety concerns of beta-carotene led to replacement of beta-carotene with lutein-zeaxanthin in the AREDS formulation,”.
  • At 10 years, the researchers found that the addition of lutein-zeaxanthin had a significant beneficial effect for reducing progression to late AMD (P = .04) compared with the main effects of omega-3 fatty acids, low zinc and low beta-carotene (P .5)..
  • Additionally, patients randomized to receive lutein-zeaxanthin had a lower risk for developing lung cancer (P = .35) compared with those who received beta-carotene (P = .02)..
  • “Incremental beneficial effects of lutein-zeaxanthin in the efficacy of AREDS2 supplements continues when comparing lutein-zeaxanthin with beta-carotene in the follow-on, especially for neovascular AMD,”…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close